Form of adoptive transfer where cells with antitumor activity are transferred to the tumor-bearing host in order to mediate tumor regression. The lymphoid cells commonly used are lymphokine-activated killer (LAK) cells and tumor-infiltrating lymphocytes (TIL). This is usually considered a form of passive immunotherapy. (From DeVita, et al., Cancer, 1993, pp.305-7, 314)
Form of adoptive transfer where cells with antitumor activity are transferred to the tumor-bearing host in order to mediate tumor regression. The lymphoid cells commonly used are lymphokine-activated killer (LAK) cells and tumor-infiltrating lymphocytes (TIL). This is usually considered a form of passive immunotherapy. (From DeVita, et al., Cancer, 1993, pp.305-7, 314)
Immunosuppression by the administration of increasing doses of antigen. Though the exact mechanism is not clear, the therapy results in an increase in serum levels of allergen-specific IMMUNOGLOBULIN G, suppression of specific IgE, and an increase in suppressor T-cell activity
Form of adoptive transfer where cells with antitumor activity are transferred to the tumor-bearing host in order to mediate tumor regression. The lymphoid cells commonly used are lymphokine-activated killer (LAK) cells and tumor-infiltrating lymphocytes (TIL). This is usually considered a form of passive immunotherapy. (From DeVita, et al., Cancer, 1993, pp.305-7, 314)
Immunosuppression by the administration of increasing doses of antigen. Though the exact mechanism is not clear, the therapy results in an increase in serum levels of allergen-specific IMMUNOGLOBULIN G, suppression of specific IgE, and an increase in suppressor T-cell activity
Cancer -- Immunotherapy -- Congresses. : Policy issues in the clinical development and use of immunotherapy for cancer treatment : proceedings of a workshop / Erin Balogh, Kimberly Maxfield, Margie Patlak, and Sharyl J. Nass, rapporteurs ; National Cancer Policy Forum, Board on Health Care Services, Health and Medicine Division, the National Academies of Sciences, Engineering, Medicine
Immunotherapy -- ethics. : New treatments for addiction : behavioral, ethical, legal, and social questions / Committee on Immunotherapies and Sustained-Release formations for Treating Drug Addiction ; Henrick J. Harwood and Tracy G. Myers, editors
Genitourinary organs -- Cancer -- Immunotherapy : Neoadjuvant immunotherapy treatment of localized genitourinary cancers : multidisciplinary management / Andrea Necchi, Philippe E. Spiess, editors
Immunotherapy -- legislation & jurisprudence. : New treatments for addiction : behavioral, ethical, legal, and social questions / Committee on Immunotherapies and Sustained-Release formations for Treating Drug Addiction ; Henrick J. Harwood and Tracy G. Myers, editors
2004
1
Melanoma -- Immunotherapy. : M-VAX TM - a treatment for patients with advanced stage III melanoma : assessment report
Immunotherapy -- trends : Immunotherapy in 2020 : visions and trends for targeting inflammatory disease / A. Radbruch [and others], editors
2007
1
Tuberculosis -- Immunotherapy : Advances in host-directed therapies against tuberculosis / Petros C. Karakousis, Richard Hafner, Maria Laura Gennaro, editors
Immunotoxicologia. : Allergy and immunotoxicology in occupational health -- the next step / Takemi Otsuki, Mario Di Gioacchino, Claudia Petrarca, editors
Semisynthetic conjugates of various toxic molecules, including RADIOACTIVE ISOTOPES and bacterial or plant toxins, with specific immune substances such as IMMUNOGLOBULINS; MONOCLONAL ANTIBODIES; and ANTIGENS. The antitumor or antiviral immune substance carries the toxin to the tumor or infected cell where the toxin exerts its poisonous effect
